rudy dekeyser 21/04/05. origin of the species mission & objectives creating an innovative...

Rudy Dekeyser

21/04/05

• origin of the species

• mission & objectives

• creating an innovative environment

• is basic high quality research compatible with tech transfer?

Origin of the species

Ghent

Antwerp

Louvain

Diepenbeek

Brussels


Step 1. Flemish government evaluates the life sciences research [1994]


The 1994 conclusions: big names in science

but lack of structural support critical mass translation in industrial activities


Dedicate a certain volume of an existing granting body to life sciences research danger:

slice it thin lack of sustainability

Establish a novel independent research institution

danger: disturb the equilibrium lag phase

The conventional approach:


Step 2. The VIB concept

unite existing quality build synergy and critical mass

researchtech transfer


VIB – unite existing quality

60 biotech teams in 5 universities

evaluation

select 9 excellent teams


U2 U3

U4 U5

U1

VIB vzw


VIB – create critical mass

Flemish government invests 5y x 25M€ = 125.000.000 €

= doubling research budget overnight= creating critical mass

Framework agreement:• long term commitment • in depth evaluation every 5 year


VIB – create synergy

Framework agreement with universities key output: scientific publications

www.nature.com/reviews/genetics

752 / October 2004 / volume 5

http://www.nature.com/reviews/genetics







Framework agreement with universities tech transfer:

• IPR– joint ownership– management: VIB– costs: VIB

• marketing/exploitation: VIB

Origin of the speciesVIB – create synergy Framework agreement with universities

tech transfer - return

€ € €patent cost

inventors VIB

50 univ 50 VIB

Department

40 401010



Framework agreement with universities tech transfer – return

UNIV : 10 + 40 + 40 = 90%

VIB : 10 + 40 + 40 = 90%


VIB – key facts & figures

foundation : 1996 legal entity : not-for-profit field : life sciences budget 2004 : ~ 60 mio € headcount : ~ 850

Mission

Molecular sciences to improve the quality of life

Objectives

conduct frontline basic research

translate inventions into products for the benefit of society

inform the public

VIB - Research

Major fields: Oncology Cardiovascular/angiogenesis Neurobiology Inflammation/immunology Developmental biology Plant system biology Microbiology

TNF-R55

TNFmembrane

VIB - Research

p50 p65IB

p50 p65

IBUb

UbUb

PP

nucleus

p50 p65NF-B dependent genes

TNF-R75

FADD

casp8

apoptosis PP

IKK

IKK/ IKK /

MAP3K

TRADD

TRAF2

PP

inflammation

Ub

RIP

ABIN

A20

VIB - Research

healthy colon

Colitis ulcerosa Crohn’s disease

Recombinant L.lactis, expressing IL-10

Novel treatment for IBD in clinical trial

VIB - Research

2 3 4 5 6 7 81

Cleavage

mRNA

gDNA

CTG1(-540)

ATG(1)

-1154-2578

-634G/CVEGF189

L-VEGFProtein

G/A

C/A

G/C

VEGF mice show adult onset ALS phenotype

Reduced levels of VEGF increase the risk for ALS

VEGF promoter polymorphisms reduce VEGF expression

H

16OArg

N

ArcN

C16O

H

C18O

18O

Ex.: Heatmap of ratios of amino-terminal peptides for 700 IDs from T-Lymphocyte

x

y

VIB - ResearchQuantitative N-teromics

According to reverse phase chromatography position

According to ratio (O18/O16)

VIB - Research

VIB – Tech Transfer

Tech Transfer = Technology Transfer

= Knowledge Transfer

= the movement of knowledge between different parties

= the transfer of knowledge from an academic institution to industry

= patenting, licensing and establishing start-ups

= mining of knowledge

=> optimize knowledge creation

VIB - Research Target : frontline Create the environment:

recognise excellence

top performance => budget

low performance => budget excellence bonus recruit internationally

39 nationalities

58% European countries

23 % Asia

11% N&S America

6,5 % Africa

1% Australia

0

10

20

30

% I

NT

Po

std

oc

s1997 1999 2001 2003

% internationalisation

VIB – Research

international recognition



up to date infrastructure

UGent-VIB research building

VIB - Research

Target : frontline Create the environment:


up to date infrastructure

access to advanced technology platforms

VIB microarray facility

(Source: PhD thesis Kris Gevaert, 2000)

VIB proteomics core facility

VIB Genetic Service Facility

sequencing

STR-genotyping

SNP discovery

SNP analysis

VIB technology – model organisms

yeast drosophila zebrafish

xenopus mouse arabidopsis

VIB technologiesBio-informatics


Stimulate debate and interaction GLC VIB seminar VIB newsletter science clubs PhD program

VIB - Research

Quality assurance:

• IAB

Institutional Advisory Board 2004

VIB - Research

Quality assurance IAB SAB strategic plan organigram [critical density]

VIB - Research

VIB - Research

Quality assurance

IAB SAB strategic plan organigram performance criteria

VIB - Research

Performance criteria:

scientifically

≥ 45 publications in IF > 10 journals

≥ 125 publications in IF > 5 journals

education

≥ 35 PhD’s

tech transfer

≥ 25 patent applications

50% granted

≥ 5 mio € industry funding

VIB - Research

X 2.7 X 3.3

IF > 10IF > 5

16

53

0

10

20

30

40

50

60

1995 2004

69

187

0

20

40

60

80

100

120

140

160

180

200

1995 2004

• facilitate the commercialisation of research results for the benefit of society • promote economic growth• job creation• generate research € to dept.

records of invention

IPR

agreements existing

companies

start-ups

research



Disclosure and recording of inventions

Policy: adapt to academic environment pro-active minimize administrative hurdles treat with priority

VIB - Tech Transfer

0

10

20

30

40

50

60

96 97 98 99 2000 2001 2002 2003 2004

# ROI

Inventions

VIB - Tech TransferROI-benchmark

3

2,5

2

1,5

1

0,5

0V IB

M €

/RO

I

Cal TechARCH

StanfordCan. Inst.

US Inst.US Univ.

VIB - Tech Transfer

0

5

10

15

20

25

30

35

95 96 97 98 99 2000 2001 2002 2003 2004

# P A

# patent applications

VIB - Tech Transfer

Patent applications (PA)

VIB : 48% ROI => PA

Benchmark : 50% ROI => PA


Priority filing

EUUSUK

PCT filing

2nd filing

Search report

National phase

Written opinion

Preliminary Examination Report

Granting

portfolio management


0

5000

10000

15000

20000

25000

30000

35000

'96 '97 '98 '99 '00 '01 '02 '03 '04

Budgets/year - cumulative

VIB - Tech Transfer

Pfizer Novartis Johnson & Johnson Solvay Abbott Bayer

Licensing/R&D: some collaborators

Innogenetics Tibotec Galapagos CropDesign Ablynx Tigenix

VIB - Tech Transfer

conceptualize and write business plan strengthen the technology/product base via inlicensing assist in bringing the team in place road show to raise venture money assist in the due diligence process

VIB operates in a very hands-on manner by playing the role of seed financier:

Start-up: basic principles

VIB - Tech Transfer

Start-up: case study - nanobody

Broad application spectrum

• diagnostics/proteomics

• therapeutics

• immuno-affinity

• feed/food

VIB - Tech Transfer

Start-up: case study – nanobody

(1) Technology building

secured access to 3 basic patents covering product claims and production methodology (VUB)

filed 6 more patent families

> 40 patent applications and patents

(2) Strategic investments:

VIB grant complemented with:

• tech transfer project

• IWT grant

VIB - Tech Transfer

Start-up: case study – nanobody

(3) Business plan (Ablynx)(4) Attract lead investor (GIMV)(5) Establish legal entity (VIB + GIMV)(6) Attract CEO (M. Vaeck, ex-COO Ceres)(7) Ad interim management

• recruit first employees

• rent lab space

• furnish labs

• establish contacts with potential licensees

Ablynx nv

Biopharma Foundation : 2001 Location : Ghent CEO : Dr. Mark Vaeck Venture Capital 1st round : 5 M € Investors : GIMV, BFV, Sofinnova, Gilde Venture Capital 2nd round : 25 M € New investors : Abingworth, Alta Partners

Employees : 40

Devgen nv

Biopharma & agbio

Foundation : 1997

Location : Ghent

CEO : Dr. Thierry Bogaert

Venture Capital 1st round : 9.4 M €

Investors 1st round : GIMV, Abingworth, BVF

Venture Capital 2nd round : 29 M €

New investors : Advent, LSP, Rendex, ING, DV, KBC, M&M

Employees : 95

CropDesign nv

Agbio Foundation : 1998 Location : Ghent CEO: : Dr. Johan Cardoen Venture Capital 1st round : 11 M USD Investors 1st round : GIMV, Atlas Venture, Sofinnova,

BFF Venture Capital 2nd round : 25.6 M € New Investors : Gilde, ING, DV, Burrill Agbio, KBC,

Technolife 2010

Employees : 70

Venture Capital 3th round : 16 M€

Peakadilly nv

Biopharma Foundation : 2004 Location : Ghent CEO : Koen Kas Capital 1st round : VIB Income : 3 mio € Employees : 10

Tech Transfer - 2004

0

20

40

60

80

100

120

140

160

180

200

'97 '98 '99 '00 '01 '02 '03 '04

Totaal

Start-ups: employees

VIB start-up

Benefit for society:

multiple therapeutics under development novel agronomically improved crop varieties

under deveopment

VIB - Tech Transfer

Innogenetics

VIB Bio-incubator 2

VIB Bio-incubator 1

Innovation& Incubation centre 2 (University of Ghent)

Innovation & Incubation centre 1 (University of Gent)

Crop Design

Bayer Bio Science research facilities University of Ghent/VIB

DeVGen

DeVGen

Service Center for biotech

Buildings planned or under construction

Ghent Technology Park

Conclusion

scientific output and quality improved significantly

tech transfer output has increased from almost zero to significant

Balancing science & Tech Transfer

science technology basic applied

Ye

arly

av

g #

pu

bs

Groups without collaboration

Groups with collaboration

Source: K. Debackere et al., in prep.


Table 1a – average number of SCIE publications (1998-2000)

Inventors Non-inventors

Complete sample 35,8 11,7

Sample without outliers

(# pubs < 90)

22,8 12,1

Source: K. Debackere et al., in prep.


Conclusion:

High quality basic science & tech transfer are compatible

rudy dekeyser 21/04/05. origin of the species mission & objectives creating an innovative...

Documents

vib slide

vib research slide

year slide

public slide

vib research v target

vib microarray facility

vib concept v

vib costs